• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

    2.455 +0.125 (+5.36%)
    Streaming Delayed Price Updated: 12:53 PM EDT, Jul 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,392,919
    Open 2.370
    Bid (Size) 2.450 (4,500)
    Ask (Size) 2.460 (3,800)
    Prev. Close 2.330
    Today's Range 2.340 - 2.530
    52wk Range 1.330 - 2.360
    Shares Outstanding 31,056,238
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
    From Inhibikase Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +25.9%
    +25.9%
    1 Month
    +31.3%
    +31.3%
    3 Month
    +27.2%
    +27.2%
    6 Month
    +36.4%
    +36.4%
    1 Year
    +24.0%
    +24.0%

    More News

    Read More
    News headline image
    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum ↗
    Via Chartmill
    News headline image
    Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Thursday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Which stocks are moving after the closing bell on Wednesday? ↗
    Via Chartmill
    News headline image
    Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
    From Inhibikase Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Inhibikase Posts Wider Loss in Q2 ↗
    Via The Motley Fool
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Inhibikase Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Inhibikase Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Inhibikase Therapeutics, Inc. - Common Stock trade on?
    Inhibikase Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock?
    The ticker symbol for Inhibikase Therapeutics, Inc. - Common Stock is IKT on the Nasdaq Stock Market
    What is the current price of Inhibikase Therapeutics, Inc. - Common Stock?
    The current price of Inhibikase Therapeutics, Inc. - Common Stock is 2.455
    When was Inhibikase Therapeutics, Inc. - Common Stock last traded?
    The last trade of Inhibikase Therapeutics, Inc. - Common Stock was at 07/24/26 12:53 PM ET
    What is the market capitalization of Inhibikase Therapeutics, Inc. - Common Stock?
    The market capitalization of Inhibikase Therapeutics, Inc. - Common Stock is 76.24M
    How many shares of Inhibikase Therapeutics, Inc. - Common Stock are outstanding?
    Inhibikase Therapeutics, Inc. - Common Stock has 76M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.